

Remarks

Claims 1, 5, 13, 16-18, 22-23, 30, 43-46, 49, 51, 53, 55-57, 59, 63, 68-71, 87-90 and 92-118 were allowed in the Notice of Allowance mailed May 23, 2002.

As it is believed that no new matter has been added by the above amendments to claims 23, 44, 45, 46, 49, 51, 53, 55 and 102, entry and consideration of this amendment is respectfully requested.

A Marked Up copy of the amended claims is appended to this amendment as required by 37 C.F.R. §1.121.

Applicants also submit with this Amendment a Petition To Correct Inventorship Under 37 C.F.R. 1.48 (b) requesting deletion of inventors Janos Tibor Kodra and Anker Steen Jorgensen from the above-captioned patent application.

As stated in the accompanying Petition Under 37 C.F.R. 1.48 (b), the correct inventors were named in the application when filed. However, the prosecution of the application has resulted in the amendment and cancellation of claims so that less than all of the originally named inventors are the actual inventors of the invention being claimed in the application.

Applicants therefore have deleted Janos Tibor Kodra and Anker Steen Jorgensen as inventors.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,


Date: August 23, 2002

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123


23650
PATENT TRADEMARK OFFICE






"Marked-Up" Copy Of Amended Claims

23. (Amended) A compound according to claim 22, wherein D is




wherein R¹⁶, R¹⁷, R¹⁸ and R¹⁹ are as defined in claim 1].

44. (Amended) A compound according to claim 43, wherein E is




[wherein m, p and R²³ to R³⁵ are as defined in claim 1].

45. (Amended) A compound according to claim 44, wherein E is




[wherein p, R²³, R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³⁰, R³⁴ and R³⁵ are as defined in claim 1].

46. (Amended) A compound according to claim 45, wherein E is



wherein R²³, R²⁴, R²⁵, R²⁶, R²⁷, R³⁴ and R³⁵ are as defined in claim 1].


49. (Amended) A compound according to claim 45, wherein E is



wherein R²³ and R²⁴ are as defined in claim 1].

51. (Amended) A compound according to claim 49, wherein R²³ and R²⁴ independently are selected from hydrogen, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkylidene, phenoxy, phenyl, -C(O)NR³⁶R³⁷ and -OC(O)NH-phenyl, of which the phenyl moiety optionally may be substituted with -OCF₃, [wherein R³⁶ and R³⁷ are as defined in claim 1,] or R²³ and R²⁴ together form the radical -(CH₂)_t-CR⁴⁰R⁴¹-(CH₂)_l-, -O-(CH₂)_t-CR⁴⁰R⁴¹-(CH₂)_l-O-, -S-(CH₂)_t-CR⁴⁰R⁴¹-(CH₂)_l-S-[, wherein t, l, R⁴⁰ and R⁴¹ are as defined in claim 1].


53. (Amended) A compound according to claim 46, wherein E is



wherein R²⁵, R²⁶ and R²⁷ are as defined in claim 1].

55. (Amended) A compound according to claim 53, wherein R²⁵, R²⁶ and R²⁷ independently are selected from hydrogen, halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy, C₃₋₈-cycloalkyl, C₄₋₈-cycloalkenyl, -CF₃, -OCF₃ or -NR⁴²R⁴³[, wherein R⁴² and R⁴³ are as defined in claim 1].

102. (Amended) A compound according to claim 23, wherein D is



[wherein R¹⁶, R¹⁷ and R¹⁸ are as defined in claim 1].